# A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

> **NCT02139943** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 352 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02139943
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139943, "A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02139943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*